Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (Annals of the Rheumatic Diseases, 2016)

(untitled) - Westhovens, R; Taylor, P; Alten, R; Pavlova, D; Enriquez-Sosa, F; Mazur, M; Greenwald, M; Van der Aa, A; Vanhoutte, F; Tasset, C; Harrison, P